LAURA BURGESON: Open Payments
NPI 1962467977 · HAYDEN, ID. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,070 in 63 payments from 14 companies in 2025. Trend: 2023 $446 · 2024 $867 · 2025 $1,070
Food & beverage: $1,070
| Company | Payments | Amount |
|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | 12 | $180 |
| AstraZeneca Pharmaceuticals LP | 8 | $166 |
| Novartis Pharmaceuticals Corporation | 7 | $149 |
| GlaxoSmithKline, LLC. | 14 | $139 |
| Novo Nordisk Inc | 6 | $122 |
| Amgen Inc. | 3 | $67 |
| Ardelyx, Inc. | 4 | $63 |
| Calliditas Therapeutics US Inc. | 2 | $40 |
| Mannkind Corporation | 1 | $36 |
| Vifor Pharma, Inc. | 2 | $33 |
Products named: Kerendia, FARXIGA, BENLYSTA, Ozempic, Vanrafia, IBSRELA, KRYSTEXXA, TARPEYO.
Industry payments across ID — which companies pay providers there.
